Evidence map›Paper›PMID 34994602›Full record

ArticleJCO precision oncology2021

Reply to P. Gazzaniga et al.

Mohamed Bouchahda, Raphael Saffroy, Abdoulaye Karaboué, Jocelyne Hamelin, Pasquale Innominato, Faouzi Saliba, Nelly Bosselut, Antoinette Lemoine, Francis Lévi

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in JCO precision oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Mohamed BouchahdaMohamed Bouchahda, MD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, Clinique Saint Jean L'Ermitage, Melun, France; Medical Oncology Unit, Clinique du Mousseau, Evry, France; Raphael Saffroy, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Abdoulaye Karaboué, MD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, GHI Le Raincy-Montfermeil, Montfermeil, France; Jocelyne Hamelin, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Pasquale Innominato, MD, PhD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom; Faouzi Saliba, MD, PhD, Centre Hépato Biliaire, AP-HP, Hôpital Paul Brousse (APHP), Villejuif, France; Nelly Bosselut, MD and Antoinette Lemoine, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; and Francis Lévi, MD, PhD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom.ORCID 0000-0002-3392-8265
Raphael SaffroyMohamed Bouchahda, MD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, Clinique Saint Jean L'Ermitage, Melun, France; Medical Oncology Unit, Clinique du Mousseau, Evry, France; Raphael Saffroy, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Abdoulaye Karaboué, MD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, GHI Le Raincy-Montfermeil, Montfermeil, France; Jocelyne Hamelin, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Pasquale Innominato, MD, PhD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom; Faouzi Saliba, MD, PhD, Centre Hépato Biliaire, AP-HP, Hôpital Paul Brousse (APHP), Villejuif, France; Nelly Bosselut, MD and Antoinette Lemoine, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; and Francis Lévi, MD, PhD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom.ORCID 0000-0002-9878-3669
Abdoulaye KarabouéMohamed Bouchahda, MD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, Clinique Saint Jean L'Ermitage, Melun, France; Medical Oncology Unit, Clinique du Mousseau, Evry, France; Raphael Saffroy, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Abdoulaye Karaboué, MD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, GHI Le Raincy-Montfermeil, Montfermeil, France; Jocelyne Hamelin, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Pasquale Innominato, MD, PhD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom; Faouzi Saliba, MD, PhD, Centre Hépato Biliaire, AP-HP, Hôpital Paul Brousse (APHP), Villejuif, France; Nelly Bosselut, MD and Antoinette Lemoine, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; and Francis Lévi, MD, PhD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom.ORCID 0000-0003-2074-2557
Jocelyne HamelinMohamed Bouchahda, MD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, Clinique Saint Jean L'Ermitage, Melun, France; Medical Oncology Unit, Clinique du Mousseau, Evry, France; Raphael Saffroy, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Abdoulaye Karaboué, MD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, GHI Le Raincy-Montfermeil, Montfermeil, France; Jocelyne Hamelin, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Pasquale Innominato, MD, PhD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom; Faouzi Saliba, MD, PhD, Centre Hépato Biliaire, AP-HP, Hôpital Paul Brousse (APHP), Villejuif, France; Nelly Bosselut, MD and Antoinette Lemoine, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; and Francis Lévi, MD, PhD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom.ORCID 0000-0003-4222-0792
Pasquale InnominatoMohamed Bouchahda, MD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, Clinique Saint Jean L'Ermitage, Melun, France; Medical Oncology Unit, Clinique du Mousseau, Evry, France; Raphael Saffroy, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Abdoulaye Karaboué, MD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, GHI Le Raincy-Montfermeil, Montfermeil, France; Jocelyne Hamelin, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Pasquale Innominato, MD, PhD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom; Faouzi Saliba, MD, PhD, Centre Hépato Biliaire, AP-HP, Hôpital Paul Brousse (APHP), Villejuif, France; Nelly Bosselut, MD and Antoinette Lemoine, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; and Francis Lévi, MD, PhD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom.ORCID 0000-0002-0653-8261
Faouzi SalibaMohamed Bouchahda, MD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, Clinique Saint Jean L'Ermitage, Melun, France; Medical Oncology Unit, Clinique du Mousseau, Evry, France; Raphael Saffroy, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Abdoulaye Karaboué, MD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, GHI Le Raincy-Montfermeil, Montfermeil, France; Jocelyne Hamelin, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Pasquale Innominato, MD, PhD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom; Faouzi Saliba, MD, PhD, Centre Hépato Biliaire, AP-HP, Hôpital Paul Brousse (APHP), Villejuif, France; Nelly Bosselut, MD and Antoinette Lemoine, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; and Francis Lévi, MD, PhD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom.
Nelly BosselutMohamed Bouchahda, MD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, Clinique Saint Jean L'Ermitage, Melun, France; Medical Oncology Unit, Clinique du Mousseau, Evry, France; Raphael Saffroy, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Abdoulaye Karaboué, MD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, GHI Le Raincy-Montfermeil, Montfermeil, France; Jocelyne Hamelin, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Pasquale Innominato, MD, PhD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom; Faouzi Saliba, MD, PhD, Centre Hépato Biliaire, AP-HP, Hôpital Paul Brousse (APHP), Villejuif, France; Nelly Bosselut, MD and Antoinette Lemoine, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; and Francis Lévi, MD, PhD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom.
Antoinette LemoineMohamed Bouchahda, MD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, Clinique Saint Jean L'Ermitage, Melun, France; Medical Oncology Unit, Clinique du Mousseau, Evry, France; Raphael Saffroy, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Abdoulaye Karaboué, MD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, GHI Le Raincy-Montfermeil, Montfermeil, France; Jocelyne Hamelin, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Pasquale Innominato, MD, PhD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom; Faouzi Saliba, MD, PhD, Centre Hépato Biliaire, AP-HP, Hôpital Paul Brousse (APHP), Villejuif, France; Nelly Bosselut, MD and Antoinette Lemoine, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; and Francis Lévi, MD, PhD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom.
Francis LéviMohamed Bouchahda, MD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, Clinique Saint Jean L'Ermitage, Melun, France; Medical Oncology Unit, Clinique du Mousseau, Evry, France; Raphael Saffroy, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Abdoulaye Karaboué, MD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Medical Oncology Unit, GHI Le Raincy-Montfermeil, Montfermeil, France; Jocelyne Hamelin, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; Pasquale Innominato, MD, PhD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom; Faouzi Saliba, MD, PhD, Centre Hépato Biliaire, AP-HP, Hôpital Paul Brousse (APHP), Villejuif, France; Nelly Bosselut, MD and Antoinette Lemoine, MD, Oncogenetics Department, APHP, Université Paris-Saclay, Paul Brousse Hospital, Villejuif, France; and Francis Lévi, MD, PhD, Medical Oncology Department, Paul Brousse Hospital, Villejuif, France; UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France; Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom.ORCID 0000-0003-1364-7463

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34994602

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.